Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
presence of RA classified by ACR 2010 revised criteria for at least 3 months before screening
must have been taking MTX for at least 3 months before randomization and must currently be on a stable dose of MTX for at least 4 weeks before randomization.
At Baseline: Disease activity criteria defined by \>6 tender joints out of 68 and \>6 swollen joints out of 66 and with at least 1 of the following at screening: Anti-CCP antibodies positive OR Rheumatoid Factor positive and with at least 1 of the following at screening: hsCRP ≥ 10 mg/L OR ESR ≥ 28
You may not be if
RA patients functional status class IV according to the ACR 1991 revised criteria
Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or IL-17 receptor
Previous exposure ever to an anti-TNF-a agent or any other immunomodulatory biologic agent (experimental or approved)
Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, or morphine)
Any therapy by intra-articular injections (e.g. corticosteroid, hyaluronan) required for treatment of arthritis within 4 weeks before randomization
